Related Experiment Video
Updated: Feb 28, 2026
09:07
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
598
Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Silvia Sanchez-Ramon, Angel L Corbi, Agueda Garcia Fidalgo
1Centro de Investigaciones Biologicas, CSIC, c./ Ramiro de Maeztu, 9, 28040 Madrid, Spain.
Current Pharmaceutical Design
|September 3, 2016
Summary
Subcutaneous immunoglobulin (SCIg) offers comparable immunomodulatory effects to intravenous immunoglobulin (IVIg) for autoimmune neurological diseases, with enhanced patient safety and autonomy. Despite benefits, SCIg faces limited approved uses, highlighting a need for broader adoption.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Recent evidence suggests subcutaneous immunoglobulin (SCIg) has similar immunomodulatory capacity to intravenous immunoglobulin (IVIg) in autoimmune neurological diseases.
- SCIg offers improved patient safety, autonomy, and cost-effectiveness compared to IVIg.
- Despite demonstrated benefits, SCIg has limited approved indications, and adoption for other autoimmune conditions faces resistance.
Purpose of the Study:
- To review the immunomodulatory mechanisms of immunoglobulin (Ig).
- To present current hypotheses on the clinical and immunological advantages of SCIg over IVIg.
- To discuss the pharmacokinetic features influencing SCIg's efficacy.
Main Methods:
- Review of cumulative evidence from clinical trials, observational studies, and case reports.
- Analysis of existing literature on immunoglobulin (Ig) mechanisms of action.
- Evaluation of pharmacokinetic data comparing SCIg and IVIg.
Main Results:
- SCIg demonstrates comparable immunomodulatory capacity to IVIg in autoimmune neurological diseases.
- SCIg offers superior safety and patient autonomy profiles.
- SCIg presents a cost-saving advantage in healthcare resource utilization.
Conclusions:
- SCIg is a viable and advantageous alternative to IVIg for autoimmune neurological conditions.
- The pharmacokinetic properties of SCIg contribute to its clinical and immunological benefits.
- Overcoming resistance to SCIg adoption is crucial for patient benefit and healthcare efficiency.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
01:29Inflammatory Bowel Disease IV: Pharmacological Management
860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
860
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:25Immunodeficiency Diseases
2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.7K